Part 1: What is PH-HFpEF?
Sanjiv Shah, M.D. (Northwestern University)
April 18, 2024
Part 2: Is PH-HFpEF Treatable?
Sanjiv Shah, M.D. (Northwestern University)
April 18, 2024
Part 3: Key Observations from the Levosimendan Phase 2 HELP Study
Daniel Burkhoff, M.D., Ph.D. (Cardiovascular Research Foundation)
April 18, 2024
Part 4: Impact of IV Levosimendan Therapy on Hemodynamics and Exercise Dynamics from the HELP Study
Barry Borlaug, M.D. (Mayo Clinic)
April 18, 2024
Part 5: Treatment with Oral Levosimendan Therapy in the HELP Open Label Extension Study
Barry Borlaug, M.D. (Mayo Clinic)
April 18, 2024
Part 6: Disease Prevalence and Reason To Address Significant Unmet Need in Patients with PH-HFpEF
Javed Butler, M.D., M.P.H., M.B.A. (Baylor Scott & White)
April 18, 2024